Literature DB >> 24811005

Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis.

Kerstin Göbel1, Michael K Schuhmann, Susann Pankratz, David Stegner, Alexander M Herrmann, Attila Braun, Johanna Breuer, Stefan Bittner, Tobias Ruck, Heinz Wiendl, Christoph Kleinschnitz, Bernhard Nieswandt, Sven G Meuth.   

Abstract

Lymphocyte adhesion and subsequent trafficking across endothelial barriers are essential steps in various immune-mediated disorders of the CNS, including MS. The molecular mechanisms underlying these processes, however, are still unknown. Phospholipase D1 (PLD1), an enzyme that generates phosphatidic acid through hydrolysis of phosphatidylcholine and additionally yields choline as a product, has been described as regulator of the cell mobility. By using PLD1-deficient mice, we investigated the functional significance of PLD1 for lymphocyte adhesion and migration in vitro and after myelin oligodendrocyte glycoprotein (MOG)35-55 -induced EAE, a model of human MS. The lack of PLD1 reduced chemokine-mediated static adhesion of lymphocytes to the endothelial adhesion molecules vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) in vitro, and was accompanied by a decreased migratory capacity in both blood brain barrier and cell migration models. Importantly, PLD1 is also relevant for the recruitment of immune cells into the CNS in vivo since disease severity after EAE was significantly attenuated in PLD1-deficient mice. Furthermore, PLD1 expression could be detected on lymphocytes in MS patients. Our findings suggest a critical function of PLD1-dependent intracellular signaling cascades in regulating lymphocyte trafficking during autoimmune CNS inflammation.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Central nervous system inflammation; Experimental autoimmune encephalomyelitis; Lymphocyte migration; Multiple sclerosis; Phospholipase D1 (PLD1)

Mesh:

Substances:

Year:  2014        PMID: 24811005     DOI: 10.1002/eji.201344107

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  The phospholipase D superfamily as therapeutic targets.

Authors:  Michael A Frohman
Journal:  Trends Pharmacol Sci       Date:  2015-02-03       Impact factor: 14.819

2.  Measuring Phospholipase D Enzymatic Activity Through Biochemical and Imaging Methods.

Authors:  F Philip; E E Ha; M A Seeliger; M A Frohman
Journal:  Methods Enzymol       Date:  2016-10-22       Impact factor: 1.600

Review 3.  Physiological and pathophysiological roles for phospholipase D.

Authors:  Rochelle K Nelson; Michael A Frohman
Journal:  J Lipid Res       Date:  2015-04-29       Impact factor: 5.922

4.  BCALM (AC099524.1) Is a Human B Lymphocyte-Specific Long Noncoding RNA That Modulates B Cell Receptor-Mediated Calcium Signaling.

Authors:  Sarah C Pyfrom; Chaz C Quinn; Hannah K Dorando; Hong Luo; Jacqueline E Payton
Journal:  J Immunol       Date:  2020-06-22       Impact factor: 5.422

5.  Phospholipase D1 expression analysis in relapsing-remitting multiple sclerosis patients.

Authors:  Mohammad Mahdi Eftekharian; Tahereh Azimi; Soudeh Ghafouri-Fard; Arezou Sayad; Mir Davood Omrani; Shaghayegh Sarrafzadeh; Roghayeh Abbasalipourkabir; Mehrdokht Mazdeh; Mohammad Taheri
Journal:  Neurol Sci       Date:  2017-02-22       Impact factor: 3.307

6.  IL-17-triggered downregulation of miR-497 results in high HIF-1α expression and consequent IL-1β and IL-6 production by astrocytes in EAE mice.

Authors:  Kai Shan; Rongrong Pang; Chenhui Zhao; Xiaomei Liu; Wenxing Gao; Jing Zhang; Dan Zhao; Yingwei Wang; Wen Qiu
Journal:  Cell Mol Immunol       Date:  2017-05-01       Impact factor: 11.530

7.  Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.

Authors:  Won Chan Hwang; Doona Song; Hyesung Lee; Changmok Oh; Seong Hun Lim; Hyeon Jeong Bae; Nam Doo Kim; Gyoonhee Han; Do Sik Min
Journal:  Exp Mol Med       Date:  2022-09-21       Impact factor: 12.153

8.  D-series Resolvins activate Phospholipase D in phagocytes during inflammation and resolution.

Authors:  Ramya Ganesan; Karen M Henkels; Krushangi Shah; Xavier De La Rosa; Stephania Libreros; Nagarjuna R Cheemarla; Charles N Serhan; Julian Gomez-Cambronero
Journal:  FASEB J       Date:  2020-10-12       Impact factor: 5.191

9.  Phospholipase D2 loss results in increased blood pressure via inhibition of the endothelial nitric oxide synthase pathway.

Authors:  Rochelle K Nelson; Jiang Ya-Ping; John Gadbery; Danya Abedeen; Nicole Sampson; Richard Z Lin; Michael A Frohman
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

Review 10.  Mammalian phospholipase D: Function, and therapeutics.

Authors:  M I McDermott; Y Wang; M J O Wakelam; V A Bankaitis
Journal:  Prog Lipid Res       Date:  2019-12-09       Impact factor: 16.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.